RPHM实时信号 | 通过Getagraph.com最大化利润

购买 115171 min ago

@ $1.715

发出时间: 10 Feb 2024 @ 00:54

回报率: -2.92%

上一信号: Feb 9 - 23:42

上一信号: 出售

回报率: 0.42 %

Live Chart Being Loaded With Signals

Commentary (30 Apr 2024 @ 00:24):

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases...

Stats
今日成交量	46 935.00
平均成交量	190 059
市值	55.46M
EPS	$0 ( 2024-03-25 )
下一个收益日期	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.710
ATR14	$0.00400 (0.24%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-28	Hall Ashley	Sell	15 625	Stock option (right to buy)
2023-08-28	Hall Ashley	Buy	15 625	Common Stock
2023-08-28	Hall Ashley	Sell	15 625	Common Stock
2023-07-26	Grey Michael G	Sell	50 000	Common Stock
2023-06-23	Novo Holdings A/s	Sell	100 000	Common Stock

INSIDER POWER
49.68
Last 95 transactions
Buy: 16 929 845 \| Sell: 55 923 583

音量相关性

長: 0.25 (neutral)

短: 0.05 (neutral)

Signal:(60.998) Neutral

Reneo Pharmaceuticals, 相关性

10 最正相关
PYXS	0.915
XPON	0.867
SGTX	0.851
XOG	0.84
SGEN	0.839
HJLI	0.828
SATS	0.827
NTRA	0.822
BTBD	0.814
OTTR	0.813

10 最负相关
ALT	-0.872
LMRKN	-0.824
ISTR	-0.815
HOUR	-0.813
BSBK	-0.812
MYFW	-0.807
RNRG	-0.806
CFFN	-0.805
VWE	-0.805
AMRB	-0.803

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Reneo Pharmaceuticals, 相关性 - 货币/商品

-0.50
( neutral )

-0.73
( moderate negative )

0.00
( neutral )

0.81
( strong )

Reneo Pharmaceuticals, 财务报表

Annual	2022
营收:	$0
毛利润:	$-529 000 (0.00 %)
EPS:	$-2.04

FY	2022
营收:	$0
毛利润:	$-529 000 (0.00 %)
EPS:	$-2.04

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-5.11

FY	2020
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-2.50

Financial Reports:

No articles found.

Reneo Pharmaceuticals,

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.